Dutch Clinic is First in Country to Treat Cancer Patients with Elekta’s Agility Beam-shaping Solution for Radiation Therapy

        Print
| Source: Elekta AB
Nijmegen, THE NETHERLANDS, Oct. 15 – The first of three newly acquired Elekta
Synergy® treatment systems equipped with Agility™* 160-leaf multi-leaf
collimator (http://www.elekta.com/agility) (MLC) is now up and running
clinically at Radboud University Nijmegen Medical Center – making the clinic the
first in the Netherlands to use Agility. The first patient, a 48-year-old woman,
was treated on September 10 and clinicians have treated 70 additional patients
since then, encompassing a wide range of cancers.

“Our first experiences with Agility have gone perfectly – the high leaf speed of
Agility has made beam delivery speed much faster, especially with IMRT
[Intensity Modulated Radiation Therapy] plans,” says René Monshouwer, Ph.D.,
Clinical Physicist at Radboud. “And, comparing the system with Agility to one
without Agility, the leaf transmission is lower.”

Dr. Monshouwer adds that the high resolution leaves of Agility and low
transmission will help Radboud begin using Agility in stereotactic treatments in
the next few months.

“These are more complex treatments involving small structures in close proximity
to organs-at-risk, so we expect Agility to benefit those treatments,” he says.
“Then, once we switch from IMRT to Volumetric Modulated Arc
Therapy (http://www.elekta.com/vmat) [VMAT] for those cases, we will see a big
advance in the quality and speed of treatment.”

Elekta reinvented beam shaping, creating a solution that boasts leaf speeds that
are twice as fast as conventional devices. The 160 5 mm leaves can interdigitate
to enable treatment of island targets and multiple targets in a single session,
and optical leaf positioning technology improves accuracy and increases the
reliability and seamlessness of beam shaping. The exceptionally low leaf
transmission of less than 0.5 percent enhances treatment delivery while reducing
integral dose. The integrated whole results in a sophisticated multi-functional
beam-shaping solution.

Two of the three Elekta Synergy systems (http://www.elekta.com/synergy) that
Radboud recently acquired will come equipped with Agility as well, a second
system for the Nijmegen satellite facility and one for a satellite clinic in
Boxmeer, the former becoming clinically operational in November 2012. The
Synergy systems with Agility join four other existing Elekta linear accelerators
at Radboud University Nijmegen Medical Center. At least one of the systems in
Radboud also will be upgraded to Agility.

Learn more about Agility at www.elekta.com/agility.

*Agility is not available for sale or distribution in all markets. Please
contact the local Elekta representative for details.

# # #

For further information, please contact:
Johan Andersson Melbi, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: johan.anderssonmelbi@elekta.com
Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on October 15, 2012.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both healthcare providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,400 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.